Chen and Yu described the possibility of using COH34, a poly(ADP-ribose) glycohydrolase inhibitor, as a potentiator of CDDP, doxorubicin, temozolomide, and camptothecin against a wide panel of cell lines representing various types of human cancers, including PEO1/4 [48]. The gene discussed is PARG; the disease is cancer.